Cargando…

Role of dopamine in the pathophysiology of Parkinson’s disease

A pathological feature of Parkinson’s disease (PD) is the progressive loss of dopaminergic neurons and decreased dopamine (DA) content in the substantia nigra pars compacta in PD brains. DA is the neurotransmitter of dopaminergic neurons. Accumulating evidence suggests that DA interacts with environ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhi Dong, Yi, Ling Xiao, Wang, Dennis Qing, Lim, Tit Meng, Tan, Eng King
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506345/ https://www.ncbi.nlm.nih.gov/pubmed/37718439 http://dx.doi.org/10.1186/s40035-023-00378-6

Ejemplares similares

The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis
por: Zhou, Zhi Dong, et al.
Publicado: (2022)

LINGO-1 and Neurodegeneration: Pathophysiologic Clues for Essential Tremor
por: Zhou, Zhi-dong, et al.
Publicado: (2012)

The Therapeutic Implications of Tea Polyphenols against Dopamine (DA) Neuron Degeneration in Parkinson’s Disease (PD)
por: Zhou, Zhi Dong, et al.
Publicado: (2019)

Spike-Timing-Dependent Plasticity Mediated by Dopamine and its Role in Parkinson’s Disease Pathophysiology
por: Madadi Asl, Mojtaba, et al.
Publicado: (2022)

An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson’s Disease
por: Schechter, Meir, et al.
Publicado: (2021)

Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD)
por: Zhou, Zhi Dong, et al.
Publicado: (2016)

Role of MicroRNAs in Parkinson’s Disease
por: Goh, Suh Yee, et al.
Publicado: (2019)

Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson’s disease
por: Benazzouz, Abdelhamid, et al.
Publicado: (2014)

Editorial: The Role of Neurovascular Unit in Neurodegeneration
por: Zhou, Zhi Dong, et al.
Publicado: (2022)

Mitophagy and reactive oxygen species interplay in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson’s disease
por: Zhou, Zhi Dong, et al.
Publicado: (2019)

Mild cognitive impairment in Parkinson’s disease: a distinct clinical entity?
por: Wen, Ming-Ching, et al.
Publicado: (2017)

Dopamine Receptors and Parkinson's Disease
por: Hisahara, Shin, et al.
Publicado: (2011)

Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology
por: Pan-Montojo, Francisco, et al.
Publicado: (2014)

Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease
por: Marie, Anaıs, et al.
Publicado: (2021)

New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease
por: Tan, Jolene Su Yi, et al.
Publicado: (2020)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Immunotherapy trials in Parkinson’s disease: challenges
por: Xiao, Bin, et al.
Publicado: (2023)

Targeting gasdermin E in neurodegenerative diseases
por: Zhou, Zhi Dong, et al.
Publicado: (2023)

Oxidative Stress and Neuroinflammation in Parkinson’s Disease: The Role of Dopamine Oxidation Products
por: Chakrabarti, Sasanka, et al.
Publicado: (2023)

Historical Perspective: Models of Parkinson’s Disease
por: Chia, Shyh Jenn, et al.
Publicado: (2020)

Tau in the Pathophysiology of Parkinson’s Disease
por: Pan, Lina, et al.
Publicado: (2021)

Pathophysiology and Symptomatology of Drooling in Parkinson’s Disease
por: Polychronis, Sotirios, et al.
Publicado: (2022)

Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice
por: Vanan, Sarivin, et al.
Publicado: (2020)

Antioxidants inhibit neuronal toxicity in Parkinson's disease‐linked LRRK2
por: Angeles, Dario C., et al.
Publicado: (2016)

Cell replacement for Parkinson’s disease: advances and challenges
por: Xiao, Bin, et al.
Publicado: (2023)

The Role of DJ-1 in Cellular Metabolism and Pathophysiological Implications for Parkinson’s Disease
por: Mencke, Pauline, et al.
Publicado: (2021)

Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments
por: Gao, Chao, et al.
Publicado: (2020)

Impaired dopamine release in Parkinson’s disease
por: Cramb, Kaitlyn M L, et al.
Publicado: (2023)

The Pathophysiology and Treatment of Essential Tremor: The Role of Adenosine and Dopamine Receptors in Animal Models
por: Kosmowska, Barbara, et al.
Publicado: (2021)

Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence
por: Peeraully, Tasneem, et al.
Publicado: (2012)

Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson’s disease
por: Goggi, Julian L., et al.
Publicado: (2020)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Impaired dopamine metabolism in Parkinson’s disease pathogenesis
por: Masato, Anna, et al.
Publicado: (2019)

Familial Parkinson's Disease/Parkinsonism
por: Tomiyama, Hiroyuki, et al.
Publicado: (2015)

Evidence of Inflammatory System Involvement in Parkinson's Disease
por: Chao, Yinxia, et al.
Publicado: (2014)

Studying the Pathophysiology of Parkinson’s Disease Using Zebrafish
por: Barnhill, Lisa M., et al.
Publicado: (2020)

Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management
por: Soliman, Heithem, et al.
Publicado: (2021)

LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson’s disease: a review
por: Chen, Meng-Ling, et al.
Publicado: (2018)

Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases
por: Zhou, Zhi Dong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i8pet0tefvks7hqstnjdgkegnt